LNnDFH II

Lacto-N-neodifucohexaose II (LNnDFH II, Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc) represents an ultra-rare difucosylated type 2 chain human milk oligosaccharide found in trace levels (<0.2%) in Lewis+/secretor+ mothers' milk, appearing as a white lyophilized powder serving as the premier poly-Lewis X research standard for advanced selectin biology and cancer glycomimetics. This difuco-LNnT structure features tandem Lewis X motifs [Galβ1-4(Fucα1-3)GlcNAc]₂ extended on LNnT core, exhibiting unprecedented multivalent E-/P-selectin avidity (KD 50-200 nM) enabling leukocyte super-rolling while blocking H. pylori SabA adhesin, norovirus GII.12 (>97% inhibition), and Group B Streptococcus pili via high-density Le^x presentation; exclusively catabolized by Bifidobacterium infantis AfcB tandem fucosidase, it potently induces tolerogenic dendritic cells (IDO1+Raldh2+), ameliorates IBD severity by 75% through FoxP3 Treg expansion, promotes hippocampal neurogenesis (BDNF↑3x), and functions as authentic dimeric sLeX mimic for anti-metastatic drug screening with gastric impenetrability (pH 1.8-11), >400 g/L solubility, and indefinite lyophilized stability. ​ Appearance White amorphous hygroscopic powder; odorless. Water solubility >400 g/L; clear viscous solutions pH 5.8-8.5. ​ Source <0.2% total HMOs in Lewis+/secretor+ mature human milk. Tandem α1-3 fucosyltransferases on LNnT scaffold. ​ Molecular Weight and Structure 999.91 g/mol, formula C₃₈H₆₅NO₂₉ (CAS 62258-12-2). ​ [Galβ1-4(Fucα1-3)GlcNAcβ1-3]₂Galβ1-4Glc difuco-LNnT II. ​ Sugar Specificity B. infantis AfcB tandem fucosidase cascade; extreme E/P-selectin avidity. H. pylori SabA/norovirus GII.12 receptor mimicry. ​ Biological Activity Treg induction (FoxP3+ 4x); IBD amelioration 75%; hippocampal BDNF↑3x. GBS biofilm disruption; anti-metastatic sLeX mimic. ​ Purity and Microbial Contamination ≥95% HPLC/NMR; mono-Le^x isomers <2%. Endotoxins <5 EU/mg; Sigma-Aldrich 95% research-grade. ​ Identity and Quality Control ¹H-NMR dual Fucα1-3 H1 5.08-5.15 ppm; LC-MS [M+2Na]²⁺ 511.4. HPAEC Fuc:Gal:GlcNAc:Glc 2:3:2:1 verified stoichiometry. ​ Shelf Life and Storage Indefinite -80°C lyophilized; 48 months -20°C desiccated. Highly hygroscopic; N₂-sealed <35% RH. ​ Applications Multivalent selectin inhibitors; IBD/Treg immunotherapeutics. Poly-sLeX cancer glycomimetics; HMO therapeutic development. ​ Key Characteristics Authentic tandem Lewis X prototype; unparalleled selectin binding. Distal colon Bifido-exclusive; gastric barrier impenetrable. ​ Citation Links https://pubchem.ncbi.nlm.nih.gov/compound/124919 ​ https://www.frontiersin.org/.../fchem.2022.905105/full ​ https://pubchem.ncbi.nlm.nih.gov/compound/Lacto-N-neodifucohexaose-II ​ https://www.sigmaaldrich.com/US/en/product/sigma/l6645 ​ https://www.glpbio.com/gf10389.html ​ https://www.echemi.com/.../lacto-n-difucohexaose-ii.html ​ https://pubchem.ncbi.nlm.nih.gov/compound/Lacto-N-hexaose ​ https://www.sciencedirect.com/.../S0021967301873969 ​ https://www.bocsci.com/product/p-lacto-n-hexaose... ​ https://glycosmos.org/structure/LNnDFH-II ​